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Protocol
AbstrACt
Introduction The human papillomavirus (HPV) vaccine, 
administered in early adolescence, can substantially reduce 
cervical cancer incidence and mortality. However, lack of 
written parental consent is a key reason why some young 
women do not receive the vaccine. The national legal 
framework allows girls to be vaccinated without parental 
consent provided they are deemed Gillick competent, but 
there is some reticence about vaccinating without written 
parental consent. Self-consent procedures are being 
implemented in Bristol and South Gloucestershire. This study 
will examine the implementation, acceptability and impact of 
these new procedures.
Methods and analysis Statistical analyses of routine 
data from Public Health England and the Child Health 
Information System will test if there has been an increase 
in HPV vaccination uptake in two ways: (a) Is there an 
increase when comparing before and after the change 
in our intervention sites? and (b) Does the percentage 
change in our intervention sites differ from comparison 
sites (similar to our intervention sites in terms of initial 
HPV uptake, ethnicity and deprivation levels) in England 
where no such intervention took place and how? For the 
process evaluation, we will develop a logic model and 
use questionnaires, observations and audio-recorded 
interviews with young women, school nurses, school staff 
and parents to examine the context, implementation of 
self-consent and response to the new procedures.
Ethics and dissemination The University of Bristol 
Faculty of Health Sciences Research Ethics Committee 
and the National Health Service Health Research Authority 
provided approvals for the study. We will produce a report 
with recommendations about self-consent procedures in 
conjunction with key stakeholders. At least two papers will 
be written for publication in peer-reviewed journals and 
for conference presentations. A summary of results will be 
shared with participating immunisation nurses, school staff, 
young people and parents as requested.
trial registration number ISRCTN49086105; Pre-results.
IntroduCtIon  
Inequalities in uptake of the human 
papillomavirus vaccine
High coverage of human papillomavirus 
(HPV) vaccination programmes in early 
adolescence can substantially reduce cervical 
cancer incidence and mortality.1 2 In the UK, 
the HPV immunisation programme, predomi-
nantly delivered through schools, is achieving 
overall high coverage, and estimates suggest 
it will save 400 women each year from devel-
oping cervical cancer.3 However, research 
suggests lower socioeconomic status (SES) 
and some ethnic groups are associated with 
lower uptake of HPV vaccination.4 5 The inci-
dence of cervical cancer has been found to 
be higher in lower socioeconomic groups5 
and these women are also less likely to access 
screening programmes than higher socio-
economic groups contributing to a higher 
mortality rate.6 Inability to access vaccina-
tion adds a further layer of health inequality. 
Furthermore, students in special schools or 
pupil referral units are much less likely to 
receive the vaccine6 and may require addi-
tional efforts by healthcare professionals to 
ensure they are vaccinated.7 
Because of the preferred age for HPV 
vaccination (12/13 years), written parental 
strengths and limitations of this study
 ► The study addresses the lack of evidence about the 
impact and acceptability of self-consent procedures 
for the school-based   human papillomavirus 
vaccination programme.
 ► The study will examine new self-consent procedures 
as they are implemented in routine practice.
 ► Although not a trial, the proposed statistical analyses 
of routine data will provide evidence of the impact of 
self-consent procedures on vaccine uptake.
 ► The process evaluation will identify barriers and 
enablers to self-consent for adolescent vaccinations.
 ► Findings from this mixed-methods study will 
inform recommendations for future practice, and 
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consent tends to be sought. However, previous research 
examining facilitators and barriers to uptake of the HPV 
vaccine has shown that a lack of written parental consent 
is a key reason why some young women do not receive 
the vaccine.8 9 Furthermore, it is a barrier with poten-
tial to reinforce health inequalities since lack of written 
parental consent may also be related to lower SES and 
some ethnic groups.8 9
self-consent for HPV vaccination
In the UK, the legal framework allows girls to be vacci-
nated without parental consent provided they are deemed 
Gillick competent.10 However, WHO has acknowledged 
difficulties over consent for HPV vaccination because of 
the age of the target group, and suggests, at the very least, 
parents should be informed of the planned vaccination 
to provide an opportunity for the child to ‘opt out’ of 
the procedure.11 In England, National Health Service 
information about HPV vaccination states: “Although, as 
a parent, you're asked to sign a consent form, it is up to 
your daughter whether she has the vaccine or not”12 and 
in Public Health England (PHE) guidance for health-
care professionals there is a lack of a clear directive about 
whether parental consent is necessary.13
This lack of clarity has implications for the vaccination 
process. Parental consent may be missing because of 
problems in returning paperwork, or because a parent is 
unwilling to allow their daughter to be vaccinated. In both 
cases, there may be young women who wish to receive 
the vaccination. However, some immunisation nurses 
and school staff appear reluctant to allow girls to make 
their own decisions about HPV vaccination because of 
concerns about generating antagonism between parents 
and the school or healthcare providers.8
The issue of vaccination without written parental 
consent needs clarification, and guidance about self-con-
sent procedures is required. However, there is a paucity of 
peer-reviewed published research on the topic of self-con-
sent for adolescent vaccinations. A study undertaken in 
the USA concluded that the inability of minors to consent 
for vaccines is a likely barrier to vaccination, and that 
interventions to increase adolescent vaccination should 
consider strategies that increase the ability of unaccom-
panied minors, particularly older minors, to receive 
vaccines within the context of legal, ethical and profes-
sional guidelines.14 Also in relation to the USA, Dempsey 
and Zimet suggest the debate over whether adolescents 
should be legally allowed to self-consent to vaccination is 
unresolved and could have a substantial impact on vacci-
nation rates.15
In her doctoral thesis, Batista-Ferrer16 examined 
consent for the HPV vaccine in schools in Bristol, UK. 
Reasons recorded for why eligible girls did not receive the 
first dose of the HPV vaccine course revealed that lack 
of a signed parental consent form was the main reason 
(45.9%), while active refusal by parents occurred much 
less frequently (11.9%). Nevertheless, research indicates 
that immunisation nurses and school staff were unwilling 
to be held accountable if young women presented for 
HPV vaccination without parental consent.7 16
PHE data for 2014/2015 show some areas in the south-
west of England with low uptake of HPV vaccination. 
For example, Bristol was ranked 112th of 119 English 
local authorities (LAs) (excluding London) and South 
Gloucestershire was 106th. Because of concerns about 
low uptake rates, staff at PHE (South West) developed 
a ‘South West Template Pathway on Self Consent for 
School Aged Immunisations’. The aim is to support 
provider organisations in implementing a self-consent 
process to support young people to easily access vaccines, 
support immunisers to feel confident about self-consent 
and to improve the uptake of immunisations.
The current research will focus on the practicality and 
acceptability of implementing the new self-consent proce-
dures, and the potential impact on overall uptake and 
health inequalities. This will involve a systematic review 
of evidence relating to consent procedures for adoles-
cent vaccinations, a process evaluation examining new 
self-consent procedures in two LAs in the south-west of 
England and an assessment of the impact of self-consent 
on overall uptake levels and in relation to SES, ethnicity 
and type of school.
MEtHods And AnAlysIs
The full study comprises three key elements: a mixed-
methods systematic review of the literature relating to 
adolescent self-consent for vaccines; process evaluation 
establishing a logic model for self-consent and examining 
the context, delivery and response to self-consent proce-
dures for the HPV vaccination programme and statistical 
analyses of routinely collected data relating to HPV vacci-
nation uptake. A protocol for the systematic review will 
be published elsewhere. Here, we focus on the statistical 
analyses of routine data and the process evaluation in 
Bristol and South Gloucestershire LAs.
the new self-consent procedures
Information about the HPV vaccine, together with forms 
requesting parental consent, is distributed to young 
women at school to take home to their parents or carers. 
Previously, young women who had not returned a written 
parental consent form were not administered the vaccine 
at school. Under the new arrangements, information and 
parental consent forms are still provided by the school 
for the young women to take home to their parents or 
carers. Those who return a completed parental consent 
form agreeing for vaccination to take place are included 
in the school-based vaccination session, but in addition 
those who do not have a signed parental consent are also 
asked to attend the session where an attempt is made by 
the immunisation nurse to gain verbal parental consent 
over the telephone. Where this is achieved, the young 
women are offered the HPV vaccine. If the parent cannot 
be contacted, the immunisation nurse assesses the young 
woman’s competence using a checklist and records this 
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in a form. If the young woman is deemed competent 
and wants to receive the vaccine, she is asked to sign the 
form. If she is not deemed competent, or there is reason 
to believe that it would cause problems at home if she 
received the vaccine without parental consent, the young 
woman is not given the vaccine. These young women are 
given information about alternative options to receive the 
vaccination, such as through a community-based clinic 
run by the immunisation team: a letter with information 
about dates is given to the young women at the school-
based session.
statistical analysis of routine data
Statistical analyses will examine whether the intervention 
(implementation of self-consent) is associated with an 
increase uptake overall and whether it has the potential 
to reduce health inequalities.
Routine PHE surveillance reports HPV uptake by 
geographical area but does not provide data on uptake by 
other factors such as ethnic group, social position or type 
of school. We will examine HPV uptake by these factors 
by extracting information from the Child Health Infor-
mation System (CHIS).17 Following on from our previous 
work,5 we will examine data in relation to the programme 
years 2014/2015 until the 2018/2019 to compare uptake 
since the two-dose HPV vaccination programme has been 
implemented. The data will be anonymised and trans-
ferred in an encrypted format from the host organisation 
to the University of Bristol where it will be securely stored 
according to the Data Protection (Amendment) Act 2003 
and University of Bristol requirements.
The following variables will be available from PHE 
through extracting anonymous aggregate information 
from routine immunisation systems and CHIS: number 
of young people offered HPV vaccination; HPV uptake by 
source (school, primary care, other); consent (parental 
written, parental verbal, young women’s self-consent); 
ethnic group; index of multiple deprivation18; childhood 
vaccinations; school year; year of birth; school; local 
government area. These data can then be used in analyses 
of HPV uptake. Measures of effect will be expressed as 
ORs and risk differences (ie, percentage of HPV uptake 
before intervention minus  percentage of HPV uptake 
during intervention).
We will test whether there has been an increase in the 
uptake of the HPV vaccination programme before and 
after the intervention in terms of risk difference (differ-
ence in two proportions and tests of null hypothesis 
that there has been no change in uptake). Initiation of 
HPV vaccination uptake is 84.5% in Bristol and 86.4% 
in South Gloucester. Each year, approximately 1900 and 
1300 (overall 3200) are invited to participate.19 There-
fore, there will be an 80% power to detect an increase in 
HPV vaccine uptake to the average in England (89.4%) 
and over 90% power to detect an increase to 95%. In 
addition, we will examine whether uptake among young 
people from less affluent areas, minority ethnic groups 
and in alternative educational settings has increased 
and whether there has been any unintended increase 
or reduction in health inequalities in relation to HPV 
uptake. We also will examine uptake for specific schools 
exposed to the intervention and assess whether there is 
an association between the intensity of implementation 
of self-consent procedures (as examined in the process 
evaluation) and HPV vaccine uptake.
The observational data will test whether there has been 
an increase in HPV vaccination uptake in two ways. First, 
is there an increase before and after the change in our 
intervention sites? Second, is there evidence that the 
percentage change in our intervention sites is different 
from other sites in England where no such intervention 
took place? In the second set of analyses, we will seek to 
select comparison sites that are similar to our interven-
tion sites in terms of ethnic diversity and social position.
Process evaluation
The process evaluation will be conducted in line with the 
Medical Research Council guidance on process evalua-
tion of complex interventions.20 An initial logic model 
will be developed, in consultation with health profes-
sionals, to show the hypothesised links between planned 
activities and inputs (self-consent procedures) and the 
sequence of short-term and medium-term outcomes 
(HPV vaccine implementation and uptake) that lead to 
desired longer-term outcomes (increased uptake, reduc-
tion in health inequalities). The initial logic model will be 
refined through experience and discussion as the study 
progresses, leading to an agreed logic model at the end 
of the study.
Context will be considered in relation to the socioeco-
logical model and will include examination of policy, 
organisational, interpersonal (family and peers) and 
intrapersonal factors. Questionnaires will be sent to a key 
contact in all secondary schools and relevant immunisa-
tion nurses in the two LAs. These will include questions 
about policies and procedures for HPV vaccination within 
schools. In addition, the researchers will compile field-
notes when conducting observations and interviews in a 
sample of schools. Context will also be explored through 
interviews with a sample of immunisation nurses, school 
staff, young people and parents.
Similarly, the implementation and response to the new 
consent procedures will be examined through: ques-
tionnaires sent to a key contact in all secondary schools 
(including alternative educational settings) (n=58) and 
relevant immunisation nurses (n=5) in the two LAs; 
audio-recorded interviews (face to face or telephone) 
with relevant immunisation nurses, and more detailed 
qualitative research in eight schools (two mainstream and 
two alternative educational settings in each LA) purpo-
sively sampled in relation to type of school, HPV uptake, 
free school meal entitlement and percentage of students 
from minority ethnic groups. In these schools, more 
in-depth research will entail: audio-recorded focus groups 
or interviews (as preferred by participants) with approxi-
mately six young women; audio-recorded interviews with 
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key school staff with responsibility for organising HPV 
vaccination sessions (one per school); observations of the 
process and setting for HPV vaccination and audio-re-
corded interviews or focus groups (as preferred by partic-
ipants) with a purposive sample of approximately six 
parents per school.
Questionnaire responses will be reported descriptively, 
showing frequencies and percentages, and further illumi-
nated by relevant free-text responses. All focus group and 
interview recordings will be transcribed verbatim and any 
potentially identifying information removed. Familiari-
sation with the data will involve two researchers reading 
and discussing the transcripts to compare and begin to 
code and categorise the data. Thematic analysis will be 
undertaken, assisted by the Framework approach to 
data management.21 Primary charts will be created using 
sections of the text relating to the context, views and expe-
riences of self-consent. Streamlined versions of primary 
charts will be produced as the process of summarising 
and coding the data progresses. Key terms and phrases 
will be retained while repetition and extraneous text will 
be removed. Overarching themes will be identified within 
which similarities and differences will be explored.
dissemination 
The Bristol Young People’s Advisory Group (YPAG) 
comprise young people aged 10–17 years who are inter-
ested in healthcare and research. They meet regularly to 
help researchers with their projects. Bristol YPAG have 
been consulted about the design of the study and partic-
ipant materials. They will also be invited to an event at 
the end of the study to consider findings and recommen-
dations with the young people, parents, immunisation 
nurses and school staff involved in the study.
We will produce a report with recommendations in rela-
tion to self-consent in conjunction with key stakeholders. 
This will be presented at events for relevant healthcare 
practitioners. At least two papers will be written for publi-
cation in peer-reviewed journals, and for presentation at 
academic conferences. We will also summarise the results 
to share with participating immunisation nurses, school 
staff, young people and their parents as requested.
suMMAry
There is currently a paucity of research into the impact 
of self-consent for adolescent vaccinations. In relation 
to the HPV vaccination programme, statistical evidence 
suggests young women from socially disadvantaged 
groups are less likely to receive the vaccine, and quali-
tative evidence suggests that the requirement for written 
parental consent acts as a barrier. This could lead to 
increased health inequalities. Written parental consent 
is not a requirement for many of these young women, 
although self-consent procedures for younger adoles-
cents are not without controversy. School staff and immu-
nisation nurses appear more comfortable with the vaccine 
being administered following receipt of a signed parental 
consent form. An opportunity has arisen in the south-west 
of England for academic researchers and public health 
practitioners to work together to examine the process 
and impact of new self-consent procedures as they are 
developed and implemented, and to produce recommen-
dations for good practice. Although this research focuses 
on the HPV vaccination programme, the findings may be 
relevant to other vaccines that are offered to adolescents 
in school settings.
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